Displaying drugs 176 - 200 of 7273 in total
Armodafinil
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A5 Inducers …
Abemaciclib
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors …
Apalutamide
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic...
Approved
Investigational
Matched Categories: … P-glycoprotein inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2C9 Inducers …
Nevirapine
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C9 Inducers ... Cytochrome P-450 CYP3A Inducers …
Rifaximin
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2C19 Inducers ... Cytochrome P-450 CYP2C8 Inducers ... Cytochrome P-450 CYP3A4 Inducers …
Baloxavir marboxil
Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation.[A39895, A251755] It is a prodrug of baloxavir with an improved absorption profile than its active metabolite due to the addition of a phenolic hydroxyl...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Ubrogepant
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
Oxybutynin
Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999]
Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A Substrates …
Vemurafenib
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP1A2 Inhibitors …
Osimertinib
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers …
Estradiol cypionate
Estradiol Cypionate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol cypionate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP1A2 Substrates …
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Inhibitors …
Crisaborole
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors (weak) …
Manidipine
Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A Substrates …
Isoniazid
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2E1 Inducers ... Cytochrome P-450 CYP2C8 Inhibitors …
Fluticasone
Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A Inhibitors …
Dacomitinib
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP2D6 Inhibitors …
Mexiletine
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2B6 Substrates …
Albendazole
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Approved
Vet approved
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 Enzyme Inducers ... Cytochrome P-450 CYP3A Substrates …
Telithromycin
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A4 Substrates …
Oxymetholone
Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth in malnourished or underdeveloped patients. Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes....
Approved
Illicit
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors ... Cytochrome P-450 CYP3A7 Inhibitors …
Fruquintinib
Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Ripretinib
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Substrates …
Nilvadipine
Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Substrates …
Chlorzoxazone
A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2A6 Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP2E1 Inhibitors …
Displaying drugs 176 - 200 of 7273 in total